Stenner-Liewen F Zippelius A Pestalozzi BC Knuth A 2006 Until recently, cancer therapy was based on three modalities: surgery, radiotherapy, and cytostatic chemotherapy. In most instances treatment of solid tumors was a surgical domain. For patients with incomplete resection or relapse after surgery, radiotherapy and chemotherapy usually offered only partial response and mostly of limited duration. By the mid-1990s visions of antibody-based therapies, vaccination strategies, and even gene-specific therapies existed but seemed far from clinical practice. United States Federal Drug Administration approval of the humanized antibody rituximab (1997) and the tyrosine kinase inhibitor imatinib (2001) has changed perceptions of oncologic treatment. These drugs turned visions into reality and led the pharmaceutical industry, clinicians, and patients to new perspectives. This article gives an overview of the development of this fourth modality in cancer therapy, so-called targeted therapy. application/pdf https://sonar.ch/global/documents/4272 eng info:eu-repo/semantics/altIdentifier/doi/10.1007/s00104-006-1262-8 info:eu-repo/semantics/altIdentifier/pmid/17109101 info:eu-repo/semantics/openAccess Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen. - 2006 Animals Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antibodies, Monoclonal, Murine-Derived Antineoplastic Agents Benzamides Cancer Vaccines Cell Survival Clinical Trials as Topic Drug Delivery Systems Humans Imatinib Mesylate Neoplasms Piperazines Protein Kinase Inhibitors Pyrimidines Rituximab Trastuzumab [Molecular targeted therapy]. http://purl.org/coar/resource_type/c_6501